Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinial Microbiology and Infectious Diseases (ECCMID)
Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that researchers will be presenting two presentations and two posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Helsinki, Finland, from May 16 - 19, 2009.
Independent researchers, Dr. Francoise van Bambecke and Dr. Sandrine Lemaire, both from Universite Catholique de Louvain, will each make oral presentations descibing the unique microbiological and pharmacodynamic properties of Rib-X's novel oxazolidinone, radezolid, during a session entitled, "Pharmacokinetics/Pharmacodynamics: Clinical Relevance", on Saturday, May 16th.
Additionally, Rib-X researchers will be presenting two posters on delafloxacin, one of which discusses the activity and efficacy of delafloxacin in a Phase 2 clinical trial for complicated Skin and Skin Structure Infections. The second poster session details the in vitro activity of delafloxacin against a large, worldwide panel of methicillin-resistant Staphylococcus aureus.
Details on the presentations and abstracts are as follows:
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. In addition to delafloxacin, Rib-X is currently in Phase 2 trials with radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections. The Rχ-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the Rχ-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes.
| Media/Investor Contact Information |
|---|
|
Gina Nugent
The Yates Network 617.460.3579 gina@theyatesnetwork.com |